These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29062521)

  • 1. Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.
    Berglas S; Jutai L; MacKean G; Weeks L
    Res Involv Engagem; 2016; 2():21. PubMed ID: 29062521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
    Rawson NSB; Stewart DJ
    Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of redactions in Canada's Common Drug Review Clinical Review Reports and how they relate to the patients' voice.
    Soprovich A; El Kurdi S; Eurich DT
    BMJ Open; 2017 Sep; 7(9):e015497. PubMed ID: 28893743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting and supporting self-management for adults living in the community with physical chronic illness: A systematic review of the effectiveness and meaningfulness of the patient-practitioner encounter.
    Rees S; Williams A
    JBI Libr Syst Rev; 2009; 7(13):492-582. PubMed ID: 27819974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A; Naci H; Neez E; Mossialos E
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
    Binder L; Ghadban M; Sit C; Barnard K
    Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.